Trial Profile
A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms VAROCE
- 29 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2015 Planned number of patients changed from 220 to 252, according to ClinicalTrials.gov record.